Elevating Awareness for Sickle Cell Disease
Quercis Pharma is honored to take part in a significant event dedicated to one of the most critical health issues facing patients today: Sickle Cell Disease (SCD). They will sponsor a noteworthy session at The Galien Foundation's 2025 Patient Summit, featuring the panel titled "The Forgotten Patients: A Focus on Sickle Cell Disease." Together with leading experts, this panel aims to shed light on the ongoing healthcare disparities experienced by patients with SCD.
Prominent Discussions on Patient Care
The session, scheduled to occur at the Alexandria Center for Life Sciences, features moderator Greta Van Susteren, a well-known television journalist. This panel will gather clinicians, researchers, and advocates, all of whom will engage in conversations aimed at bridging the existing gaps in care for SCD. By spotlighting the everyday realities patients encounter, the goal is to develop patient-centered therapeutic strategies that enhance their quality of life.
Commitment to Innovation and Recognition
Quercis Pharma's involvement in this important summit underscores their commitment to serving underrepresented communities. Recently nominated for the esteemed 2025 Prix Galien USA "Best Startup" Award, Quercis has garnered recognition for its innovative contributions to healthcare. This award, often referred to as the "Nobel Prize of biopharmaceutical research," celebrates breakthroughs that significantly improve global health.
Highlighting Kinisoquin™ in Clinical Trials
Central to Quercis' nomination is their lead drug, Kinisoquin™, which is currently undergoing Phase III clinical trials. Designed to prevent venous thromboembolism (VTE) specifically in cancer patients, Kinisoquin™ represents a cutting-edge alternative to traditional blood thinners. With a focus on reducing bleeding risks, this anti-thrombotic therapy stands out for its ability to lower the risk of thrombosis more effectively.
Building a Future for Affected Patients
Daniel Drexler MD, President and CEO of Quercis USA, emphasizes that this nomination highlights their mission. He states, "We aim to create accessible therapies that can significantly improve outcomes for patients facing life-threatening conditions such as SCD and others." Through continued innovation and dedication, Quercis seeks to change the game for various disease states, emphasizing the importance of effective and safe treatment options.
Event Information
Details regarding the Patient Summit are as follows:
Date: Thursday, October 30, 2025
Location: Alexandria Center for Life Sciences, New York City
Featured Session: Panel 6 — "The Forgotten Patients: A Focus on Sickle Cell Disease"
Time: 4:05–5:05 p.m. ET
About Quercis Pharma
Quercis Pharma AG, established in Zug, Switzerland, is at the forefront of clinical-stage biopharmaceutical development. Their focus lies in creating effective inflammasome-modulating and anti-thrombotic therapies. With a robust pipeline, they are addressing significant health challenges, including Cancer Associated Thrombosis, and are well-positioned for future advancements in SCD.
Understanding The Galien Foundation
The Galien Foundation plays a vital role in promoting scientific innovation to enhance human health. Overseeing the Prix Galien USA, it recognizes remarkable achievements in biopharmaceutical research. Established in 1970, the foundation continues to inspire future medical breakthroughs, working tirelessly for better healthcare solutions.
Contact Information
For further inquiries, please reach out to:
MEDIA
Angela Gorman, President, AMWPR
Email: angela@amwpr.com
Frequently Asked Questions
What is the focus of the panel at the Patient Summit?
The panel will address the persistent care gaps for patients suffering from Sickle Cell Disease.
Who is moderating the panel discussion?
Greta Van Susteren will moderate the panel, bringing her experience in journalism to the discussion of SCD.
What recognition has Quercis Pharma recently received?
Quercis Pharma was nominated for the 2025 Prix Galien USA "Best Startup" Award for its innovative contributions to healthcare.
When is the Patient Summit scheduled?
The Patient Summit is set for October 30, 2025, at the Alexandria Center for Life Sciences.
What is the primary drug candidate of Quercis Pharma?
Constructed for patient safety, Kinisoquin™ is Quercis’s lead drug currently in Phase III trials, targeting venous thromboembolism in cancer patients.
